Erik Harris - Sep 5, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role: EVP & Chief Commercial Officer
Signature: /s/ Karah Parschauer, attorney-in-fact
Stock symbol: RARE
Transactions as of: Sep 5, 2023
Transactions value $: -$227,760
Form type: 4
Date filed: 9/6/2023, 05:51 PM
Previous filing: Jun 21, 2023
Next filing: Mar 5, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RARE	Common Stock	Sale	-$228K	-6K	-10.47%	$37.96	51.3K	Sep 5, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.95 to $38.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2	Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.95 to $38.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Includes previously reported shares of common stock underlying restricted stock units granted to the Reporting Person, which are subject to certain vesting conditions.